DarioHealth Selected as Exclusive Digital Therapeutics Provider to a Leading Benefits Brokerage
NEW YORK, Dec. 21, 2021 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced a new strategic partnership with a leading employer benefits brokerage (the “Partner”) to sell its digital therapeutic solutions for diabetes, hypertension and musculoskeletal health as part of a new premier employee health benefits product for small businesses. The product will be made available to the Partner’s more than 2,300 clients beginning in early 2022.
Small businesses in the United States represent 47% of all workers in the country, and many cite health care costs as the top challenge facing their business.[1],[2] The Partner’s new health benefits bundle offers smaller employers a way to provide valuable health benefits typically out of reach due to cost sensitivities and lack of resources to administer programs. The Partner carefully selecting solutions to create a streamlined bundle of health benefits proven to help lower costs without the administrative hassles.
The Partner selected Dario as the sole polychronic condition management solution within the preferred bundle to complement medical and pharmaceutical coverage, clinical navigation services, telehealth and centers of clinical excellence. Dario was chosen for its proven ability to deliver meaningful engagement and improved clinical results at a lower cost, supporting the Partner’s ability to deliver a best-in-class set of solutions to small employers.
“We are thrilled to be selected as the Partner’s only chronic condition solution, potentially making it possible for millions of Americans working for smaller companies to access innovative health technologies. This new product offers a wholly new way for smaller employers that otherwise lack the means to access premium benefits to discover the value of solutions like Dario, and we are excited to start those conversations,” said Rick Anderson, President and General Manager North America.
Dario is uniquely positioned to deliver results for partners of any size thanks to its therapeutics platform designed to easily scale highly personalized solutions that combine innovative technologies, digital tools and expert human support across multiple conditions. Dario’s fully integrated solution leverages a single AI-driven behavior change engine informed by billions of data points collected over ten years of consumer engagement to create a holistic, seamless member experience for sustainable engagement and clinical results.
1 U.S. Small Business Administration, 2019
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market – covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.
Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.
Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.
The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users’ health.
On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of the product being available to the Partner’s clients, the reasons Dario was chosen by the Partner and the benefits that may be realized by the Dario solution. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-selected-as-exclusive-digital-therapeutics-provider-to-a-leading-benefits-brokerage-301448894.html
SOURCE DarioHealth Corp.
